An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions

mAbs

Volumn 7, Issue 3, 2015, Pages 494-504

  Kinder, Michelle ^a   Greenplate, Allison R ^a   Strohl, William R ^a   Jordan, Robert E ^a   Brezski, Randall J ^a,b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b GENENTECH INC   (United States)

Author keywords

Antibody dependent cellular phagocytosis; Cytokine release; Fc gamma receptors; Interferon gamma; Interleukin 10; Monocyte derived macrophages; Natural killer cells

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; PROTEIN VARIANT; RANTES; STROMELYSIN; TUMOR NECROSIS FACTOR; CANCER ANTIBODY; CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; CELL KILLING; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MACROPHAGE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR MICROENVIRONMENT; DRUG EFFECTS; GENETICS; IMMUNOLOGY; NEOPLASMS; PROTEIN ENGINEERING; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CYTOKINES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MACROPHAGES; NEOPLASMS; PROTEIN ENGINEERING; TUMOR MICROENVIRONMENT;

EID: 84938488385     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1022692     Document Type: Article

References (59)

1. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-70; PMID: 20708157; http://dx. doi. org/10. 1016/j. ccr. 2010. 06. 014.
2. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13: 5133-43; PMID: 17785568; http://dx. doi. org/10. 1158/1078-0432. CCR-07-0507.
3. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Jr., Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009; 113: 3809-12; PMID: 19196657; http://dx. doi. org/10. 1182/blood-2008-10-185280.
4. Abes R, Gelize E, Fridman WH, Teillaud JL. Longlasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116: 926-34; PMID: 20439625; http://dx. doi. org/10. 1182/blood-2009-10-248609.
5. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, Lopez-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19: 1858-72; PMID: 23444227; http://dx. doi. org/10. 1158/1078-0432. CCR-12-2426.
6. Kim JM, Ashkenazi A. Fcgamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med 2013; 210: 1647-51; PMID: 23980122; http://dx. doi. org/10. 1084/jem. 20131625.
7. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210: 1685-93; PMID: 23897982; http://dx. doi. org/10. 1084/jem. 20130573.
8. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1: 32-42; PMID: 24777248; http://dx. doi. org/10. 1158/2326-6066. CIR-13-0013.
9. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumorinfiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695-710; PMID: 23897981; http://dx. doi. org/10. 1084/jem. 20130579.
10. White AL, Chan HT, Roghanian A, French RR, Mockridge CI, Tutt AL, Dixon SV, Ajona D, Verbeek JS, Al-Shamkhani A, et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011; 187: 1754-63; PMID: 21742972; http://dx. doi. org/10. 4049/jimmunol. 1101135.
11. Furness AJ, Vargas FA, Peggs KS, Quezada SA. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 2014; 35: 290-8; PMID: 24953012; http://dx. doi. org/10. 1016/j. it. 2014. 05. 002.
12. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8: 34-47; PMID: 18064051; http://dx. doi. org/10. 1038/nri2206.
13. Woof JM, Partridge LJ, Jefferis R, Burton DR. Localisation of the monocyte-binding region on human immunoglobulin G. Mol Immunol 1986; 23: 319-30; PMID: 3487030; http://dx. doi. org/10. 1016/0161-5890(86)90059-3.
14. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-25; PMID: 19018092; http://dx. doi. org/10. 1182/blood-2008-09-179754.
15. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun 2007; 75: 1424-35; PMID: 17220317; http://dx. doi. org/10. 1128/IAI. 01161-06.
16. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184: 512-20; PMID: 19949082; http://dx. doi. org/10. 4049/jimmunol. 0900847.
17. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci U S A 1988; 85: 4852-6; PMID: 3387441; http://dx. doi. org/10. 1073/pnas. 85. 13. 4852.
18. Cassatella MA, Anegon I, Cuturi MC, Griskey P, Trinchieri G, Perussia B. Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes. J Exp Med 1989; 169: 549-67; PMID: 2536067; http://dx. doi. org/10. 1084/jem. 169. 2. 549.
19. Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Abcoated tumor cells. J Clin Invest 2002; 110: 983-92; PMID: 12370276; http://dx. doi. org/10. 1172/JCI0215950.
20. Kircheis R, Halanek N, Koller I, Jost W, Schuster M, Gorr G, Hajszan K, Nechansky A. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Yspecific monoclonal antibody MB314. MAbs 2012; 4: 532-41; PMID: 22665069; http://dx. doi. org/10. 4161/mabs. 20577.
21. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95-109; PMID: 11900986; http://dx. doi. org/10. 1016/S1359-6101(01)00038-7.
22. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-37; PMID: 21997792; http://dx. doi. org/10. 1038/nri3073.
23. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-96; PMID: 20856220; http://dx. doi. org/10. 1038/ni. 1937.
24. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 1998; 188: 217-22; PMID: 9653099; http://dx. doi. org/10. 1084/jem. 188. 1. 217.
25. Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, Morreau H, van der Burg SH, Guchelaar HJ, van Hall T. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011; 17: 5668-73; PMID: 21788356; http://dx. doi. org/10. 1158/1078-0432. CCR-11-0239.
26. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-72; PMID: 19196673; http://dx. doi. org/10. 1056/NEJMoa0808268.
27. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277-86; PMID: 23518347; http://dx. doi. org/10. 1016/j. ccr. 2013. 02. 013.
28. Kinder M, Greenplate AR, Grugan KD, Soring KL, Heeringa KA, McCarthy SG, Bannish G, Perpetua M, Lynch F, Jordan RE, et al. Engineered protease-resistant antibodies with selectable cell-killing functions. J Biol Chem 2013; 288: 30843-54; PMID: 23986451; http://dx. doi. org/10. 1074/jbc. M113. 486142.
29. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20: 479-85; PMID: 18577454; http://dx. doi. org/10. 1016/j. coi. 2008. 05. 010.
30. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103: 4005-10; PMID: 16537476; http://dx. doi. org/10. 1073/pnas. 0508123103.
31. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276: 6591-604; PMID: 11096108; http://dx. doi. org/10. 1074/jbc. M009483200.
32. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007; 67: 8882-90; PMID: 17875730; http://dx. doi. org/10. 1158/0008-5472. CAN-07-0696.
33. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7: 2517-27; PMID: 18723496; http://dx. doi. org/10. 1158/1535-7163. MCT-08-0201.
34. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 2571-5; PMID: 11160318; http://dx. doi. org/10. 4049/jimmunol. 166. 4. 2571.
35. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2: 181-9; PMID: 20150767; http://dx. doi. org/10. 4161/mabs. 2. 2. 11158.
36. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68: 3863-72; PMID: 18483271; http://dx. doi. org/10. 1158/0008-5472. CAN-07-6297.
37. Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, Schmidt AP, Kruszynski M, Whitaker BP, Knight DM, et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 2008; 181: 3183-92; PMID: 18713989; http://dx. doi. org/10. 4049/jimmunol. 181. 5. 3183.
38. Brezski RJ, Oberholtzer A, Strake B, Jordan RE. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. MAbs 2011; 3: 558-67; PMID: 22123056; http://dx. doi. org/10. 4161/mabs. 3. 6. 18119.
39. Brezski RJ, Vafa O, Petrone D, Tam SH, Powers G, Ryan MH, Luongo JL, Oberholtzer A, Knight DM, Jordan RE. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A 2009; 106: 17864-9; PMID: 19815504; http://dx. doi. org/10. 1073/pnas. 0904174106.
40. Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, et al. A monoclonal antibody against hingecleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs 2014; 6: 1265-73; PMID: 25517311; http://dx. doi. org/10. 4161/mabs. 29825.
41. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6; PMID: 10742152; http://dx. doi. org/10. 1038/74704.
42. Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA, Strohl WR, et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012; 189: 5457-66; PMID: 23105143; http://dx. doi. org/10. 4049/jimmunol. 1201889.
43. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009; 100: 113-7; PMID: 19066610; http://dx. doi. org/10. 1038/sj. bjc. 6604812.
44. Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, Gerber HP. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007; 110: 4370-2; PMID: 17909075; http://dx. doi. org/10. 1182/blood-2007-06-097014.
45. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784-9; PMID: 17908969; http://dx. doi. org/10. 1158/1078-0432. CCR-07-0778.
46. Nesspor TC, Raju TS, Chin CN, Vafa O, Brezski RJ. Avidity confers FcgammaR binding and immune effector function to aglycosylated immunoglobulin G1. J Mol Recognit 2012; 25: 147-54; PMID: 22407978; http://dx. doi. org/10. 1002/jmr. 2155.
47. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7: 1401-13; PMID: 17727329; http://dx. doi. org/10. 1517/14712598. 7. 9. 1401.
48. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20: 685-91; PMID: 19896358; http://dx. doi. org/10. 1016/j. copbio. 2009. 10. 011.
49. Kim HY, Kim S, Chung DH. FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation. J Clin Invest 2006; 116: 2484-92; PMID: 16917543.
50. Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med (Berl) 2002; 80: 248-57; PMID: 11976734; http://dx. doi. org/10. 1007/s00109-001-0294-2.
51. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci U S A 2012; 109: 6181-6; PMID: 22474370; http://dx. doi. org/10. 1073/pnas. 1203954109.
52. Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 2013; 190: 4315-23; PMID: 23509345; http://dx. doi. org/10. 4049/jimmunol. 1200501.
53. Kagan JC. "Complementing" toll signaling. Sci Signal 2010; 3: pe15; PMID: 20442416.
54. Gearing AJ, Thorpe SJ, Miller K, Mangan M, Varley PG, Dudgeon T, Ward G, Turner C, Thorpe R. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 2002; 81: 41-8; PMID: 11841844; http://dx. doi. org/10. 1016/S0165-2478(01)00333-9.
55. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Bjorck L, Jordan RE. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 2008; 45: 1837-46; PMID: 18157932; http://dx. doi. org/10. 1016/j. molimm. 2007. 10. 043.
56. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-5; PMID: 11406547.
57. Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 2012; 14: R116; PMID: 22873525; http://dx. doi. org/10. 1186/bcr3240.
58. Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer 2007; 120: 1261-7; PMID: 17192924; http://dx. doi. org/10. 1002/ijc. 22426.
59. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 2003; 278: 174-9; PMID: 12403778; http://dx. doi. org/10. 1074/jbc. M208742200.